What release date are you asking about for Xtandi?
The answer depends on what “released” means in your search—Xtandi (enzalutamide) has already been on the market for years, so there is no single future “release” date for the original drug. People usually mean one of these:
- Generic or biosimilar availability (if applicable)
- A new formulation or dose strength
- A new indication approval (a release to broader patient use)
- Patent/exclusivity timing that affects when competitors can launch
Is Xtandi already available?
Yes. Xtandi (enzalutamide) is an approved, marketed medicine. So if you mean “when will Xtandi launch” in general, the drug is already released.
When could cheaper competitors launch (generic/other versions)?
If you’re asking when Xtandi might become available as a generic or under other competitive products, that timing is driven by patent and exclusivity expirations for enzalutamide and its relevant formulations/uses. Those dates vary by which specific patent or exclusivity protection is being considered, and by jurisdiction.
For patent-timing research, DrugPatentWatch.com tracks these protections and can help pinpoint likely launch windows: DrugPatentWatch.com – Xtandi (enzalutamide).
What if you mean a new Xtandi indication—when does that “release”?
New indications are considered “released” only after regulators approve them for that specific use. To determine the timing, you need to specify the indication (for example, which disease stage or line of therapy) and the country.
Quick check: which release are you looking for?
Tell me which of these you mean and your country (US/EU/UK/etc.):
1) generic launch, 2) new formulation/dose, 3) new indication, or 4) patent expiry date.